Clovis Oncology

Clovis Oncology, Inc. is a biopharmaceutical company, which engages in the acquisition, development, and commercialization of innovative anti-cancer agents in the United States, Europe, and additional international markets. Its U.S. marketed product, Rubraca (rucaparib), an oral small molecule inhibitor of poly ADP-ribose polymerase (PARP), is approved for use in the maintenance treatment and treatment of eligible adult patients with recurrent epithelial ovarian, fallopian tube, and primary peritoneal cancer, and also for the treatment of adult patients with a deleterious BRCA mutation (germline and/or somatic)-associated metastatic castration-resistant prostate cancer (mCRPC), which have been treated with androgen receptor-directed therapy and a taxane-based chemotherapy. In Europe, Rubraca is approved for use in recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer. The company was founded by Andrew R. Allen, Gillian C. Ivers-Read, Patrick J. Mahaffy, and Erle T. Mast on April 20, 2009 and is headquartered in Boulder, CO.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Clovis Oncology is a biopharmaceutical company focused on acquiring, developing and commercializing cancer treatments in the United States, Europe and other international markets. Their development programs are targeted at specific subsets of cancer, combining precision medicine with companion diagnostics to direct therapeutics to those patients most likely to benefit from them.

Clovis is joining the myriad of other big Reddit-stock winners this morning as retail traders move huge amounts of CLVS stock. The post CLVS Stock: Is a Reddit-Fueled Short Squeeze Brewing for Clovis Oncology?

CLVS Stock: Is a Reddit-Fueled Short Squeeze Brewing for Clovis Oncology?

This unloved biotech is finding new life on social media.

Why Clovis Oncology Stock Is Rocketing Higher Today

Clovis (CLVS) reported earnings 30 days ago. What's next for the stock?

Clovis (CLVS) Down 5.3% Since Last Earnings Report: Can It Rebound?

Clovis Oncology Inc. (NASDAQ: CLVS) is gearing up to present this week at the American Society of Clinical Oncology annual meeting, which runs June 4-8. The company is expected to report updated Phase 1b results on Lucitanib and Opdivo in patients with advanced solid tumors.

Could Clovis Oncology Stock Be Gearing Up For Its Next Move?

BOULDER, Colo.--(BUSINESS WIRE)---- $CLVS--Clovis Oncology Highlights Rubraca® (rucaparib) and Lucitanib Data at 2021 ASCO Annual Meeting

Clovis Oncology Highlights Rubraca® (rucaparib) and Lucitanib Data at 2021 ASCO Annual Meeting

BOULDER, Colo.--(BUSINESS WIRE)--Clovis Oncology, Inc. (NASDAQ:CLVS) announced today that it has filed a prospectus supplement with the U.S. Securities and Exchange Commission (“SEC”), under which it may offer and sell, from time to time, shares of its common stock having an aggregate offering price of up to $75,000,000 million through an “at-the-market” equity offering program (the “ATM Program”). The timing and amount of any sales will be determined by a variety of factors considered by Clovi

Clovis Oncology Announces At-The-Market Equity Offering Program

Clovis Oncology is an intriguing stock because it goes through periods of boom and bust. As an ideal stock for traders, you can build Clovis shares in a downdraft and take profits on the upswing.

Clovis Oncology: Another Upcycle Coming

Clovis (CLVS) reports lower-than-expected loss for first-quarter 2021. Lower new patient start amid COVID-19 hurts U.S. sales of Rubraca.

Clovis (CLVS) Q1 Earnings Beat, COVID-19 Hurts Rubraca Sales

Clovis Oncology, Inc. (CLVS) CEO Patrick Mahaffy on Q1 2021 Results - Earnings Call Transcript

Clovis Oncology Inc (NASDAQ: CLVS) is trading higher on Wednesday after the company reported better-than-expected first-quarter earnings. What Happened: Clovis Oncology reported an earnings loss of 64 cents per share, beating the estimate for a loss of 72 cents per share.

What Is Going On With Clovis Oncology Today?

Clovis (CLVS) delivered earnings and revenue surprises of 11.11% and -15.14%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

Clovis Oncology (CLVS) Reports Q1 Loss, Misses Revenue Estimates

BOULDER, Colo.--(BUSINESS WIRE)---- $CLVS--Clovis Oncology, Inc. (NASDAQ:CLVS) reported financial results for the quarter ended March 31, 2021, and provided an update on the Company's clinical development programs and regulatory and commercial outlook for the rest of the year. “The second quarter of 2021 marks an important moment in our commitment to targeted radionuclide therapies, as the FDA clearance of our INDs for FAP-2286 enables us to initiate the Phase 1 portion of the LuMIERE study this quarter

Clovis Oncology Announces First Quarter 2021 Operating Results

BOULDER, Colo.--(BUSINESS WIRE)---- $CLVS--Clovis Oncology to Present at the Bank of America 2021 Health Care Conference

Clovis Oncology to Present at the Bank of America 2021 Health Care Conference

BOULDER, Colo.--(BUSINESS WIRE)--Clovis Oncology, Inc. (NASDAQ: CLVS) will announce its first quarter 2021 financial results on Wednesday, May 5, 2021, before the open of the US financial markets. Clovis' senior management will host a conference call and live audio webcast at 8:30 a.m. ET to discuss the Company's results in greater detail. The conference call will be simultaneously webcast on the Clovis Oncology website www.clovisoncology.com, and a replay of the webcast will be available for 3

Clovis Oncology to Announce First Quarter 2021 Financial Results and Host Webcast Conference Call on May 5

Since July 7, 2017, Clovis has lost close to 93% of its value. Shorts have amassed a 32 million share position, but tables can turn quickly. The company has been hemorrhaging cash developing its pipeline, but investors should take note at how easy it's for them to access liquidity.

Clovis: On The Verge Of A Major Breakout?

Clovis Oncology is a highly volatile stock that rises and falls cyclically. Despite Rubraca's approval for two deadly cancer indications (ovarian and prostate), sales have been increasing modestly.

Clovis Oncology: Your Keys To Banking Profits

BOULDER, Colo.--(BUSINESS WIRE)---- $CLVS--Clovis Oncology Highlights Rubraca® (rucaparib) Clinical Data at AACR Virtual Annual Meeting 2021

Clovis Oncology Highlights Rubraca® (rucaparib) Clinical Data at AACR Virtual Annual Meeting 2021

Why Is Clovis (CLVS) Up 4.4% Since Last Earnings Report?

Investors need to pay close attention to Clovis Oncology (CLVS) stock based on the movements in the options market lately.

Are Options Traders Betting on a Big Move in Clovis Oncology (CLVS) Stock?

Clovis (CLVS) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.

Clovis (CLVS) Stock Jumps 47.7%: Will It Continue to Soar?

The stock price of Clovis Oncology Inc (NASDAQ: CLVS) increased by 47.74% on March 19. This is why it happened.

CLVS Stock Price Increased 47.74%: Why It Happened

The biotech's experimental cancer treatment demonstrated promising results in a clinical trial.

Why Clovis Oncology Stock Skyrocketed Today

Clovis Oncology Inc. (NASDAQ:CLVS) shares are gaining ground in Friday's session. The jump in the shares comes after a company announcement stating that Rubraca significantly improves progression-free survival versus chemotherapy in patients with later-line ovarian cancer associated with a BRCA mutation.

Clovis Oncology Stock Rallies: Technical Levels To Watch

Alector Inc

Marker Therapeutics Inc

Clovis Oncology, Inc. (NASDAQ: CLVS), Marker Therapeutics, Inc. (NASDAQ: MRKR) and Alector, Inc. (NASDAQ: ALEC) are among the biggest biotech gainers Friday. Clovis Jumps On Ovarian Cancer Data: Clovis announced positive results for the Phase 3 study of Rubraca in ovarian cancer.

Why Clovis Oncology, Marker Therapeutics, Alector Are Rallying Friday

Biotech company Clovis Oncology has shown promising info regarding the treatment of ovarian cancer. CLVS stock has benefitted from the data.

News for Clovis Oncology Stock (CLVS)